
Intellectual Property (Non-confidential)



Anti-Prostate Stem Cell Antigen Monoclonal Antibody



DESCRIPTION

Prostate cancer is the most commonly diagnosed cancer in the United States with approximately 1.7 million currently diagnosed and 200,000 new diagnosed cases per year. Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody IG8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response and its rapid clearance from the body. This technology covers a humanized IG8 antibody in which the majority of the mouse-derived epitopes have been removed. This humanized antibody binds PSCA with high affinity and specificity, and has been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make this anti-PSCA antibody an attractive agent for the treatment and detection of tumors expressing PSCA.

KEY ASPECTS

- Monoclonal antibody targeting Prostate Stem Cell Antigen (PSCA)
- Antibody has been humanized
- Animal data available upon request

INTELLECTUAL PROPERTY

Title	US Patent Number	Issued
Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody	8,088,908	1/3/2012
	US Patent Application	Filed
Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody	13/308/783	12/1/2011

<u>CONTACT</u>

Matthew Grunseth, M.B.S. Senior Manager, Office of Technology Licensing Telephone: (626) 471-7221 | Email: <u>mgrunseth@coh.org</u>

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.